Thrombosis
From the Journals
DOACs look safe in elective endoscopic procedures
The study also found delaying resumption of anticoagulants provided no benefit.
From the Journals
NETs a possible therapeutic target for COVID-19 thrombosis?
Feature
COVID-19 anticoagulation trials ‘paused’ for futility, safety
The trials involved are the REMAP-CAP, ACTIV-4, and ATTACC studies.
Opinion
ASH guidelines for venous thromboembolism: What family physicians need to know
A recommendation regarding the use of DOACs may ease some of the burden of monitoring patients on long-term Coumadin.
From the Journals
COVID-19 and risk of clotting: ‘Be proactive about prevention’
"We believe a systematic way of addressing this risk is best, with every patient hospitalized with COVID-19 receiving some type of...
Conference Coverage
Cost is the main hurdle to broad use of caplacizumab for TTP
“If we take finances out, I think almost every patient except those with a bleeding risk or bleeding problem should get it,” an investigator said...
Conference Coverage
No benefit from tranexamic acid prophylaxis in blood cancers
Conference Coverage
VTE prophylaxis is feasible, effective in some high-risk cancer patients
Conference Coverage
What to do when anticoagulation fails cancer patients
Conference Coverage
Liver injury linked to COVID-19–related coagulopathy
Cells that line the liver’s blood vessels produce high levels of factor VIII, a coagulation factor, when they are exposed to interleukin-6, an...
Conference Coverage
Factor XI inhibitor–based anticoagulation strategies gain ground
“When we compare the FXI inhibitors with existing anticoagulants, we don’t necessarily want to go up against the DOACs.”